Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment

Journal of the American College of Cardiology

Volumn 34, Issue 7, 1999, Pages 2088-2095

  Weissman, Neil J ^a   Tighe Jr , John F ^a   Gottdiener, John S ^a   Gwynne, John T ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; DEXFENFLURAMINE; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; ECHOCARDIOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VALVULAR HEART DISEASE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AORTIC VALVE INSUFFICIENCY; DELAYED-ACTION PREPARATIONS; DEXFENFLURAMINE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE INSUFFICIENCY; OBSERVER VARIATION; PREVALENCE; RISK FACTORS; SAFETY; SEROTONIN AGONISTS;

EID: 0033454750     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00445-3     Document Type: Article

References (43)

1. Connolly H. Heart valve disease and fen-phen. News release, July 8, 1997.
2. Connolly H.M., Crary J.L., McGoon M.D., et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 337:1997;581-588.
3. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine US Department of Health and Human Services interim public health recommendations, November 1997 . MMWR Morb Mortal Wkly Rep. 46:1997;1061-1066.
4. Newman R. Mitral valve disease associated with use of anorexigenic medications. (abstr) Ann Thorac Surg. 64:1997;294.
5. Food and Drug Administration. FDA analysis of cardiac valvular dysfunction with use of appetite suppressants, 9/17/97. http://www.fda.gov/cder/news/slides/sld001.htm; 1997.
6. Bowen R.L., Posten W.S., Miller C.C., Haddock C.K., Foreyt J.P. Echocardiographic evaluation of patients treated with anorexiant medications. (abstr) Int J Obes. 22:1998;S77.
7. Rasmussen S., Corya B., Glassman R.D. Valvular heart disease associated with fenfluramine-phentermine. (letter) N Engl J Med. 337:1997;1773.
8. Wadden T.A., Berkowitz R.I., Silvestry F., et al. The fen-phen finale a study of weight loss and valvular heart disease . Obes Res. 6:1998;278-284.
9. Kurz X., Van Erman A. Valvular heart disease associated with fenfluramine-phentermine. (letter) N Engl J Med. 337:1997;1772-1773.
10. Griffen L., Anchors M. Asymptomatic mitral and aortic valve disease is seen in half of the patients taking phen-fen. Arch Intern Med. 158:1998;102.
11. Malak J., Deprez P., Adam J.F. Valve disease associated with chronic intake of fenfluramines. (letter) J Lab Clin Med. 131:1998;475.
12. Tsui K.L., Lo K.W., Tse T.S., et al. Clinical and echocardiographic assessment for valvular abnormalities in patients taking dexfenfluramine. (abstr) J Hong Kong Coll Cardiol. 6:1998;42.
13. Wang Q., Yu C.M., Ho S.P.C., et al. Echocardiographic screening for patients on fenfluramine. (abstr) J Hong Kong Coll Cardiol. 6:1998;42.
14. Teramae C., Connolly H., Grogan M., Miller F., Seward J., Tajik J. Diet drug-related cardiac disease the Mayo Clinic echocardiographic laboratory experience . (abstr) J Am Soc Echocardiogr. 11:1998;510.
15. Wong J., Lin S., Klein A. Valvular heart disease associated with the use of anorexiant drugs. (abstr) J Am Soc Echocardiogr. 11:1998;559.
16. Orlandi Q.G., Price D., Istfan N., Davidoff R. Valvular abnormalities in asymptomatic obese individuals receiving fenfluramine and phentermine a consecutive series . (abstr) J Am Coll Cardiol. 31:1998;151A.
17. Orlandi Q., Price D., Istfan N., Joziatis B., Alfieri C., Davidoff R. Valvular abnormalities in asymptomatic obese individuals receiving fenfluramine and phentermine a consecutive series . (abstr) J Am Soc Echocardiogr. 11:1998;511.
18. Orlandi Q.G., Price D., Istfan N., et al. Valvular abnormalities in asymptomatic obese individuals receiving fenfluramine, dexfenfluramine or phentermine a consecutive series . (abstr) Circulation. 98:1998;I645.
19. Blackburn G., Chan S., Burger A., Kim J., Asinas L. Benefits and risks of fen-phen therapy. (abstr) Int J Obes. 22:1998;S76.
20. Burger A.J., Sherman H.B., Charlamb M.J., et al. Low incidence of valvular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months. (abstr) Circulation. 98:1998;I644.
21. Leite C.C., Mancini M.C., Medeiros C.J., Sbano J.C., Grinberg M., Halpern A. Echocardiographic evaluation of 70 patients using dexfenfluramine. (abstr) Int J Obes. 22:1998;S277.
22. Kancherla M., Salti H., Otting L., Bonow R., Mehlman D.J. Prevalence of valvular regurgitation in patients exposed to anorectic drugs. (abstr) J Investig Med. 46:1998;252A.
23. Kancherla M., Saiti H., Otting L., Bonow R.O., Mehlman D.J. Prevalence of valvular regurgitation in patients exposed to anorectic agents. (abstr) Circulation. 98:1998;I645.
24. Keen W.D., O'Boyle M.K. Phentermine-fenfluramine valvulopathy is uncommon. (abstr) Circulation. 98:1998;I645.
25. Caccitolo J.A., Connolly H.M., Rubenson D.S., Orsulak T.A., Edwards W.D., Schaff H.V. Operation for fenfluramine-phentermine associated valvular heart disease. (abstr) Circulation. 98:1998;I832.
26. Gross S.B., Lepor N.E., Daley W.L., Buchbinder N.A., Hickey A., Samuels B.A. Dose and duration of appetite suppressant therapy impacts incidence of valvular heart disease. (abstr) Circulation. 98:1998;I28.
27. Gross S.B., Samuels B.A., Daley W.L., et al. Combination therapy with fenfluramine-phentermine increases the risk of significant aortic insufficiency. (abstr) Circulation. 98:1998;I666.
28. Weissman N., Tighe J., Gottdiener J., Gwynne J. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine or placebo. N Engl J Med. 339:1998;725-732.
29. Helmcke F., Nanda N.C., Hsiung M.C., et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. Circulation. 75:1987;175-183.
30. Perry G.J., Helmcke F., Nanda N.C., Byard C., Soto B. Evaluation of aortic insufficiency by Doppler color flow mapping. J Am Coll Cardiol. 9:1987;952-959.
31. Ranganathan N., Lam J.H., Wigle E.D., Silver M.D. Morphology of the human mitral valve II. The valve leaflets . Circulation. 41:1970;459-467.
32. Yock P.G., Popp R.L. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 70:1984;657-662.
33. Singh J.P., Evans J., Levy D., et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (The Framingham Heart Study). Am J Cardiol. 83:1999;897-902.
34. Rosen M., Takeuchi M., Teupe C., Abadi C., Saltzman E., Pandian N. Are dexfenfluramine, fenfluramine and phentermine associated with valvular heart disease? Blinded analysis of 107 patients with matched controls. (abstr) J Am Soc Echocardiogr. 11:1998;510.
35. Gardin J, Schumacher D, Constantine G, Davis K, Leung C, Reid C. Cardiovascular evaluation of patients who previously received dexfenfluramine or phentermine/fenfluramine compared to control patients. Paper presented at 71st Scientific Sessions, American Heart Association; November 11, 1998; Dallas, Texas.
36. Shively B. Echocardiographic diagnosis, from "Anorexigen-induced cardiovascular diseases." Highlights from the 71st Scientific Sessions, American Heart Association, November 8-11, 1998, CD-ROM 1998.
37. Lopez-Jimenez F., Aldrich H.R., Kumar V., et al. Fen-phen use is not associated with an increased prevalence of significant valvular heart disease. (abstr) Circulation. 98:1998;I645.
38. Khan M.A., Herzog C.A., St. Peter J.V., et al. The prevalence of cardiac valvular disease in appetite-suppressant-treated individuals and matched unexposed control subjects. (abstr) Circulation. 98:1998;I645.
39. Jick H., Vasilakis C., Weinrauch L.A., Meier C.R., Jick S.S., Derby L.E. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. N Engl J Med. 339:1998;719-724.
40. Cannistra L.B., Cannistra A.J. Regression of multivalvular regurgitation after cessation of fenfluramine and phentermine treatment. (letter) N Engl J Med. 339:1998;771.
41. Davidoff R, McTiernan A, Constantine G, Davis K, Otto C, Bowen D. A cardiovascular evaluation of female smokers up to 4.9 years after treatment with fenfluramine: follow-up of a prospective randomized double-blind placebo-controlled trial. Paper presented at the 2nd Annual and Plenary Meeting of the Working Group on Echocardiography of the European Society of Cardiology; December 10, 1998; Trieste, Italy.
42. Wee C., Phillips R., Aurigemma G., et al. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Ann Intern Med. 129:1998;870-874.
43. Bonow R.O., Carabello B., de Leon A. Jr, et al. Guidelines for the Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Valvular Heart Disease) . J Am Coll Cardiol. 32:1998;1486-1588.